These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 29126030)

  • 41. Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study.
    Bertoglio JC; Baumgartner M; Palma R; Ciampi E; Carcamo C; Cáceres DD; Acosta-Jamett G; Hancke JL; Burgos RA
    BMC Neurol; 2016 May; 16():77. PubMed ID: 27215274
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fingolimod effect on brain volume loss independently contributes to its effect on disability.
    Sormani MP; De Stefano N; Francis G; Sprenger T; Chin P; Radue EW; Kappos L
    Mult Scler; 2015 Jun; 21(7):916-24. PubMed ID: 25662353
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience.
    D'Amico E; Patti F; Zanghì A; Lo Fermo S; Chisari CG; Zappia M
    Expert Rev Clin Pharmacol; 2018 May; 11(5):531-536. PubMed ID: 29521113
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab.
    Bianco A; Patanella AK; Nociti V; Marti A; Frisullo G; Plantone D; De Fino C; Fetta A; Batocchi AP; Rossini PM; Mirabella M
    Eur Neurol; 2015; 73(1-2):57-65. PubMed ID: 25402749
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure.
    Mehra MR; Lavie CJ; Ventura HO; Milani RV
    J Heart Lung Transplant; 2006 Jul; 25(7):834-8. PubMed ID: 16818127
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of fish and olive oil on mitochondrial ATPase activity and membrane fluidity in patients with relapsing-remitting multiple sclerosis treated with interferon beta 1-b.
    Torres-Sánchez ED; Pacheco-Moisés FP; Macias-Islas MA; Morales-Sánchez EW; Ramírez-Ramírez V; Celis de la Rosa AJ; Cid-Hernández M; Sorto-Gómez TE; Ortiz GG
    Nutr Hosp; 2018 Jan; 35(1):162-168. PubMed ID: 29565165
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis.
    Skurkovich S; Boiko A; Beliaeva I; Buglak A; Alekseeva T; Smirnova N; Kulakova O; Tchechonin V; Gurova O; Deomina T; Favorova OO; Skurkovic B; Gusev E
    Mult Scler; 2001 Oct; 7(5):277-84. PubMed ID: 11724442
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
    Simpson S; Stewart N; van der Mei I; Otahal P; Charlesworth J; Ponsonby AL; Blizzard L; Dwyer T; Pittas F; Gies P; Taylor B
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):200-7. PubMed ID: 24790215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
    Saida T; Kira J; Ueno Y; Harada N; Hirakata T
    Mult Scler Relat Disord; 2016 May; 7():102-8. PubMed ID: 27237769
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial.
    Nafissi S; Azimi A; Amini-Harandi A; Salami S; shahkarami MA; Heshmat R
    Clin Neurol Neurosurg; 2012 Sep; 114(7):986-9. PubMed ID: 22429566
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIG
    Deiva K; Huppke P; Banwell B; Chitnis T; Gärtner J; Krupp L; Waubant E; Stites T; Pearce GL; Merschhemke M
    J Neurol Neurosurg Psychiatry; 2020 Jan; 91(1):58-66. PubMed ID: 31467033
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does lipoic acid consumption affect the cytokine profile in multiple sclerosis patients: a double-blind, placebo-controlled, randomized clinical trial.
    Khalili M; Azimi A; Izadi V; Eghtesadi S; Mirshafiey A; Sahraian MA; Motevalian A; Norouzi A; Sanoobar M; Eskandari G; Farhoudi M; Amani F
    Neuroimmunomodulation; 2014; 21(6):291-6. PubMed ID: 24821457
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Draganaova-Filipova MN; Mateva NG; Miteva LD; Stanilova SA
    Scand J Clin Lab Invest; 2017 Jul; 77(4):283-288. PubMed ID: 28319417
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
    Agashivala N; Kim E
    Clin Ther; 2012 Jul; 34(7):1583-90. PubMed ID: 22749258
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of Vitamin A Supplementation on Disease Progression in Patients with Multiple Sclerosis.
    Bitarafan S; Saboor-Yaraghi A; Sahraian MA; Nafissi S; Togha M; Beladi Moghadam N; Roostaei T; Siassi F; Eshraghian MR; Ghanaati H; Jafarirad S; Rafiei B; Harirchian MH
    Arch Iran Med; 2015 Jul; 18(7):435-40. PubMed ID: 26161708
    [TBL] [Abstract][Full Text] [Related]  

  • 59. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A longitudinal real-life comparison study of natalizumab and fingolimod.
    Lanzillo R; Carotenuto A; Moccia M; Saccà F; Russo CV; Massarelli M; De Rosa A; Brescia Morra V
    Acta Neurol Scand; 2017 Sep; 136(3):217-222. PubMed ID: 27976804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.